Sotyktu Expands Potential with Successful Phase III Trials in Psoriatic Arthritis

Successful Phase III Trials:
Bristol Myers Squibb (BMS) has announced positive top-line results from two pivotal Phase III trials (POETYK PsA-1 and POETYK PsA-2) evaluating Sotyktu (deucravacitinib) in patients with psoriatic arthritis (PsA)23.

Efficacy and Safety:
Both trials met their primary endpoints, showing significant improvements in signs and symptoms of PsA after 16 weeks, as measured by the American College of Rheumatology (ACR20) scale. The safety profile was consistent with previous findings3.

Market Potential:
These results open up a new market for Sotyktu, which is currently FDA-approved only for treating moderate to severe plaque psoriasis. The drug is expected to achieve blockbuster status, with sales forecasted to reach $2.2 billion by 20303.

Patient-Reported Outcomes:
Previous studies have shown that deucravacitinib improves a broad range of patient-reported outcomes in PsA, including mental health, pain, fatigue, and physical functioning4.

Clinical Development:
The success of these trials positions Sotyktu as a potential first TYK2 inhibitor for treating PsA, addressing the need for a safe and effective oral treatment option3.

Sources:

2. https://c.firstwordpharma.com/firstwordgroup/assets/drugs/sotyktu.jpg?sa=X&ved=2ahUKEwiu1KL7xcCKAxVE38kDHd6-IBkQ_B16BAgLEAI

3. https://www.clinicaltrialsarena.com/news/bms-sees-success-in-phase-iii-sotyktu-psoriatic-arthritis-trials/

4. https://www.healio.com/news/rheumatology/20240415/deucravacitinib-improves-broad-range-of-patientreported-psoriatic-arthritis-outcomes